Printer Friendly
The Free Library
14,530,480 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Shionogi Launches Cancer Pain Analgesic OxiNorm Powder 0.5% in Japan.


Tokyo, Japan, Feb 5, 2007 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) 
 Newswire) - Shionogi & Co., Ltd. has launched OxiNorm powder 0.5% (oxycodone hydrochloride oxycodone hydrochloride

ETH-Oxydose, OxyContin, OxyFast, Oxy-IR, Oxynorm (UK), Roxicodone, Supeudol (CA)

Pharmacologic class: Opioid agonist

Therapeutic class: Narcotic analgesic

 hydrate hydrate (hī`drāt), chemical compound that contains water. A common hydrate is the familiar blue vitriol, a crystalline form of cupric sulfate. Chemically, it is cupric sulfate pentahydrate, CuSO4·5H2O. ), a powder analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs  for cancer pain, in Japan today. Licensed from Mundipharma, OxiNorm powder 0.5% is an immediate-release powder analgesic for treatment of cancer pain with the same active ingredient An active ingredient, also active pharmaceutical ingredient (or API), is the substance in a drug that is pharmaceutically active. Some medications may contain more than one active ingredient.  as OxyContin Ox·y·con·tin

A trademark for the drug oxycodone.


oxycodone hydrochloride

ETH-Oxydose, OxyContin, OxyFast, Oxy-IR, Oxynorm (UK), Roxicodone, Supeudol (CA)

Pharmacologic class: Opioid agonist
(R) Tablets, also under license from Mundipharma, which Shionogi launched in July 2003.

It is used for adjusting dosage for individual patients to obtain an optimal dose and for swift treatment of sudden pain (breakthrough pain). Combined use of sustained-release and immediate-release analgesics Analgesics Definition

Analgesics are medicines that relieve pain.
Purpose

Analgesics are those drugs that mainly provide pain relief.
 with the same active ingredient and administration route is a method for treating cancer pain recommended in the official journal of the World Health Organization (WHO) and elsewhere. The launch of OxiNorm powder 0.5% will further increase the efficacy of cancer pain management with OxyContin Tablets.

Shionogi will dedicate full efforts to appropriately promoting OxiNorm powder 0.5% and OxyContin Tablets, so that all cancer patients can lead peaceful lives free from pain.

Product Summary of OxiNorm powder 0.5%
Product name:            OxiNorm powder 0.5%
Generic name:            Oxycodone hydrochloride hydrate
Manufacturing and
 marketing approval:     October 20, 2006
NHI drug price listing:  December 1, 2006
Launch date:             February 5, 2007
Indications:             Moderate to severe pain associated
                           with all types of cancer
NHI drug price:         132.60 yen per gram (at 0.5%)


About Shionogi and Co., Ltd.

Shionogi & Co., Ltd, established in 1887 and was incorporated in 1919, is a major research-driven Japanese pharmaceutical manufacturer. The company's primary businesses are research and development, manufacturing, marketing, and import and export sales of pharmaceutical and diagnostics products. Shionogi follows a basic policy of continually providing the superior medicines essential to people's health. For more details, please visit http://www.shionogi.co.jp

Source: Shionogi and Co., Ltd.

Contact:
Public Relations Unit
Shionogi & Co., Ltd.
Osaka
Tel: +81-6-6209-7885
Fax: +81-6-6229-9596
Tokyo
Tel: +81-3-3406-8164
Fax: +81-3-3406-8099


Copyright [c] 2007 JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2007 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCN Newswires
Date:Feb 6, 2007
Words:335
Previous Article:ORIX Announces Signing of Joint Venture Agreement in Hanoi, Vietnam; Promotion of an Integrated Real Estate Development Project.
Next Article:Mitsui Chemicals to License PP Process to Thai Polypropylene.
Topics:



Related Articles
THE DECADE OF PAIN CONTROL AND RESEARCH.(Brief Article)
LABOPHARM/PURDUE PHARMA SIGN TRAMADOL LICENSING PACT.
Shionogi to Sell Shionogi Qualicaps Group to Carlyle Group.
Shionogi Launches New Quinolone Antibacterial "Avelox(R) Tablet 400mg" (Moxifloxacin Hydrochloride).
Shionogi, Purdue Pharma to Collaborate to Develop and Market New Analgesic Drug Compounds.
Sankyo's Percutaneous Absorption-Type Analgesic and Anti-inflammatory Drug Loxonin Poultice 100mg Receives Approval for Manufacture in Japan.
Takeda Pharmaceutical to Release Sustained-Release Morphine Hydrochloride Capsule.
LABOPHARM GRANTS TRAMDOL MARKETING RIGHTS TO PURDUE PHARMA.
Shionogi Obtains Manufacturing, Marketing Approval for OXINORM Powder 0.5%.
ARCHIMEDES PHARMA BEGINS PHASE III FOR NASALFENT.

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles